Marine glycan-derived therapeutics in China

Progress in Molecular Biology and Translational Science

Volumn 163, Issue , 2019, Pages 113-134

  Gao, Yanyun ^a   Zhang, Lijuan ^a   Jiao, Wenjie ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Chitosan ester (PS916); Fucoidan (FPS); Marine glycan based drugs; Oligomannurate chromium sodium (HS203); Polyguluronate sulfate sodium (PGS); Polymannuroguluronate sulfate (911); Propylene glycol alginate sodium sulfate (PSS); Propylene glycol mannuronate sulfate (PGMS); Sodium oligomannurarate (GV971)

Indexed keywords

ALGINIC ACID; CHITIN ESTER; CHITOSAN DERIVATIVE; FUCOIDIN; GLYCAN DERIVATIVE; OLIGOMANNURONATE CHROMIUM SODIUM; POLYGULURONATE SULFATE SODIUM; PROPYLENE GLYCOL ALGINATE SODIUM SULFATE; PROPYLENE GLYCOL MANNURONATE SULFATE; SODIUM OLIGOMANNURARATE; UNCLASSIFIED DRUG; POLYSACCHARIDE;

ANTIBACTERIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CHEMICAL STRUCTURE; CHINA; DRUG ACTIVITY; HUMAN; NONHUMAN; PHARMACOKINETIC PARAMETERS; ANIMAL; AQUATIC SPECIES; CHEMISTRY; CLINICAL TRIAL (TOPIC); TOXICITY TESTING;

ANIMALS; AQUATIC ORGANISMS; CHINA; CLINICAL TRIALS AS TOPIC; HUMANS; POLYSACCHARIDES; TOXICITY TESTS;

EID: 85063347658     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/bs.pmbts.2019.02.006     Document Type: Chapter

References (136)

1. Shi, Q., Wang, A., Lu, Z., Qin, C., Hu, J., Yin, J., Overview on the antiviral activities and mechanisms of marine polysaccharides from seaweeds. Carbohydr Res 453–454 (2017), 1–9.
2. de Jesus Raposo, M.F., de Morais, A.M., de Morais, R.M., Marine polysaccharides from algae with potential biomedical applications. Mar Drugs 13:5 (2015), 2967–3028.
3. Pomin, V.H., Anticoagulant motifs of marine sulfated glycans. Glycoconj J 31:5 (2014), 341–344.
4. Rodrigues, J.A.G., Queiroz, I.N.L.D., Quinderé, A.L.G., Vairo, B.C., Mourão, P.A.D.S., Benevides, N.M.B., An antithrombin-dependent sulfated polysaccharide isolated from the green alga Caulerpa cupressoides has in vivo anti-and prothrombotic effects. Cienc Rural 41:4 (2011), 634–639.
5. Vishchuk, O.S., Ermakova, S.P., Zvyagintseva, T.N., The fucoidans from brown algae of far-eastern seas: anti-tumor activity and structure–function relationship. Food Chem 141:2 (2013), 1211–1217.
6. Souza, M.C.R.D., Marques, C.T., Dore, C.M.G., Rocha, H.A.O., Leite, E.L., Antioxidant activities of sulfated polysaccharides from brown and red seaweeds. J Appl Psychol 19:2 (2007), 153–160.
7. Buck, C.B., Thompson, C.D., Roberts, J.N., Müller, M., Lowy, D.R., Schiller, J.T., Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog, 2(7), 2006, e69.
8. Li, L., Li, L., Guo, C., Evaluation of in vitro antioxidant and antibacterial activities of Laminaria japonica polysaccharides. J Med Plant Res 4:21 (2010), 2194–2198.
9. Kumar, T.V., Lakshmanasenthil, S., Geetharamani, D., Marudhupandi, T., Suja, G., Suganya, P., Fucoidan—a α-d-glucosidase inhibitor from Sargassum wightii with relevance to type 2 diabetes mellitus therapy. Int J Biol Macromol 72 (2015), 1044–1047.
10. Wan-Loy, C., Siew-Moi, P., Marine algae as a potential source for anti-obesity agents. Mar Drugs 14:12 (2016), 222–240.
11. Vo, T.S., Ngo, D.H., Kang, K.H., Jung, W.K., Kim, S.K., The beneficial properties of marine polysaccharides in alleviation of allergic responses. Mol Nutr Food Res 59:1 (Jan 2015), 129–138.
12. Iwasaki, A., Medzhitov, R., Regulation of adaptive immunity by the innate immune system. Science, 327(5963), 2010, 291.
13. Gao, Y., Liu, W., Wang, W., Zhao, X., Wang, F., Polyguluronate sulfate (PGS) attenuates immunological liver injury in vitro and in vivo. Int J Biol Macromol 114 (2018), 592–598.
14. Hoang, M.H., Kim, J.-Y., Lee, J.H., You, S., Lee, S.-J., Antioxidative, hypolipidemic, and anti-inflammatory activities of sulfated polysaccharides from Monostroma nitidum. Food Sci Biotechnol 24:1 (2015), 199–205.
15. Aquino, R.S., Grativol, C., Mourao, P.A., Rising from the sea: correlations between sulfated polysaccharides and salinity in plants. PLoS One, 6(4), 2011, e18862.
16. Zeng, Y., Han, Z., Qiu, P., et al. Salinity-induced anti-angiogenesis activities and structural changes of the polysaccharides from cultured Cordyceps Militaris. PLoS One., 9(9), 2014, e103880.
17. Hao, C., Xu, H., Yu, L., Zhang, L., Heparin: an essential drug for modern medicine. Prog Mol Biol Transl Sci 163 (2019), 1–19.
18. Hao, C., Sun, M., Wang, H., Zhang, L., Wang, W., Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci 163 (2019), 21–39.
19. Dou, H., Song, A., Jia, S., Zhang, L., Heparinoids danaparoid and sulodexide as clinically used drugs. Prog Mol Biol Transl Sci 163 (2019), 55–74.
20. Hemker, H.C., A century of heparin: past, present and future. J Thromb Haemost 14:12 (Dec 2016), 2329–2338.
21. Pan, J., Qian, Y., Zhou, X., et al. Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat Biotechnol, 28(3), 2010, 203.
22. Zhang, L., Glycosaminoglycans in development, health and disease. Preface. Prog Mol Biol Transl Sci 93 (2010), xvii–xviii.
23. Wang, W., Wang, S., Guan, H., The antiviral activities and mechanisms of marine polysaccharides: an overview. Mar Drugs 10:12 (2012), 2795–2816.
24. Hao, C., Gao, L., Zhang, Y., et al. Acetylated chitosan oligosaccharides act as antagonists against glutamate-induced PC12 cell death via Bcl-2/Bax signal pathway. Mar Drugs 13:3 (2015), 1267–1289.
25. Shan, M., Feng, N., Zhang, L., Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond—a review of 31 years clinical experiences in China. Prog Mol Biol Transl Sci 163 (2019), 75–93.
26. Wang, J., Geng, L., Yue, Y., Zhang, Q., Use of fucoidan to treat renal diseases: a review of 15 years of clinic studies. Prog Mol Biol Transl Sci 163 (2019), 95–111.
27. Pan, J., Qian, Y., Zhou, X., et al. Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat Biotechnol 28:3 (Mar 2010), 203–207 [author reply 207–211].
28. Liu, H., Zhang, Z., Linhardt, R.J., Lessons learned from the contamination of heparin. Nat Prod Rep 26:3 (Mar 2009), 313–321.
29. Pan, J., Qian, Y., Zhou, X., Lu, H., Ramacciotti, E., Zhang, L., Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways. J Biol Chem 285:30 (2010), 22966–22975.
30. Pan, J., Qian, Y., Zhou, X., et al. Identification of chemically sulfated/desulfated glycosaminoglycans in contaminated heparins and development of a simple assay for the detection of most contaminants in heparin. Glycobiol Insights 2010:2 (2010), 1–12.
31. Guerrini, M., Beccati, D., Shriver, Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:6 (Jun 2008), 669–675.
32. Qian, Y., Pan, J., Zhou, X., Weiser, P., Lu, H., Zhang, L., Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. Prog Mol Biol Transl Sci 93 (2010), 395–421.
33. Qian, Y., Pan, J., Zhou, X., et al. Contaminated heparin-affected patient plasmas are associated with activated contact systems. Clin Appl Thromb Hemost 16:3 (2010), 261–265.
34. Pan, J., Qian, Y., Weiser, P., et al. Glycosaminoglycans and activated contact system in cancer patient plasmas. Prog Mol Biol Transl Sci 93 (2010), 473–495.
35. Hahn, T., Lang, S., Ulber, R., Muffler, K., Novel procedures for the extraction of fucoidan from brown algae. Process Biochem 47:12 (2012), 1691–1698.
36. Rodriguez-Jasso, R.M., Mussatto, S.I., Pastrana, L., Aguilar, C.N., Teixeira, J.A., Microwave-assisted extraction of sulfated polysaccharides (fucoidan) from brown seaweed. Carbohydr Polym 86:3 (2011), 1137–1144.
37. Rioux, L.E., Turgeon, S.L., Beaulieu, M., Characterization of polysaccharides extracted from brown seaweeds. Carbohydr Polym 69:3 (2007), 530–537.
38. Li P, Chen X, Xing R, Yu H, Liu S. n.d. A method for extracting brown algae polysaccharide sulfate. CN Patent 200710014573.X.2007-9-19.
39. Zhang, Q., Li, Z., Xu, Z., Niu, X., Zhang, H., Effects of fucoidan on chronic renal failure in rats. Planta Med, 69(6), 2003, 537.
40. Bian, L., Xia, P., La, Y., Observation of the curative effect of Shen Hai Kang in the treatment of chronic renal failure. Chin J Integr Tradit West Nephrol 5:1 (2004), 45–46.
41. Liu, J.M., Bignon, J., Haroun-Bouhedja, F., et al. Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. Anticancer Res, 25(3B), 2005, 2129.
42. Ikeguchi, M., Yamamoto, M., Arai, Y., et al. Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncol Lett 2:2 (2011), 319–322.
43. Yan, M.D., Yao, C.J., Chow, J.M., et al. Fucoidan elevates microRNA-29b to regulate DNMT3B-MTSS1 axis and inhibit EMT in human hepatocellular carcinoma cells. Mar Drugs 13:10 (2015), 6099–6116.
44. Xu, Y., Xu, J., Ge, K., Tian, Q., Zhao, P., Guo, Y., Anti-inflammatory effect of low molecular weight fucoidan from Saccharina japonica on atherosclerosis in apoE-knockout mice. Int J Biol Macromol 118:pt A (2018), 365–374.
45. Geng, L., Hou, N., Zhang, M., et al. Comparative study of the effect of different fucoidans from Sargassum maclurei and Saccharina japonica on FGFs/FGFR signaling activation in BaF3 cells. Int J Biol Macromol 107:Pt B (2018), 2429–2435.
46. Chen, A., Ying, L., Liu, J., et al. The structure property and endothelial protective activity of fucoidan from Laminaria japonica. Int J Biol Macromol 105:Pt 2 (2017), 1421–1429.
47. Fedorov, S.N., Ermakova, S.P., Zvyagintseva, T.N., Stonik, V.A., Anticancer and cancer preventive properties of marine polysaccharides: some results and prospects. Mar Drugs 11:12 (2013), 4876–4901.
48. Ermakova, S., Kusaykin, M., Trincone, A., Tatiana, Z., Are multifunctional marine polysaccharides a myth or reality?. Front Chem, 3, 2015, 39.
49. Wang, X., Wang, X., Jiang, H., et al. Marine polysaccharides attenuate metabolic syndrome by fermentation products and altering gut microbiota: an overview. Carbohydr Polym 195 (Sep 1 2018), 601–612.
50. Lee, Y.E., Kim, H., Seo, C., et al. Marine polysaccharides: therapeutic efficacy and biomedical applications. Arch Pharm Res 40:9 (Sep 2017), 1006–1020.
51. Li, Z., Zhang, Q., Niu, X., Zhang, H., Xu, Z., Fucoidan. Fine Spec chem 11:2 (2003), 16–17.
52. Thuy, T.T.T., Ly, B.M., Van, T.T.T., et al. Anti-HIV activity of fucoidans from three brown seaweed species. Carbohydr Polym, 115, 2015, 122.
53. Lim, J.D., Lee, S.R., Kim, T., et al. Fucoidan from Fucus vesiculosus protects against alcohol-induced liver damage by modulating inflammatory mediators in mice and HepG2 cells. Mar Drugs 13:2 (2015), 1051–1067.
54. Li, J., Chen, K., Li, S., et al. Pretreatment with fucoidan from Fucus vesiculosus protected against ConA-induced acute liver injury by inhibiting both intrinsic and extrinsic apoptosis. PLoS One, 11(4), 2016, e0152570.
55. Li, B., Lu, F., Wei, X., Zhao, R., Fucoidan: structure and bioactivity. Molecules 13:8 (2008), 1671–1695.
56. Du, L., 40 cases of chronic renal failure treated by Haikunshenxi capsules. Shaanxi J Tradit Chin Med 30:12 (2009), 1582–1583.
57. Shi, D., Study on clinical effect of Haikunshenxi capsules in treatment of patients with chronic renal failure and its antioxidant mechanism. J Clin Exp Med 14:4 (2015), 307–310.
58. Han, Y., Lv, Z., Jiang, T., Wang, Y., Bioanalysis and pharmacokinetics of chitosan ester in rabbit serum by HPLC with postcolumn fluorescence derivatization. J Chromatogr B 845:1 (2007), 138–142.
59. Ding, H., Zhu, Q., Xu, L., Wu, B., Li, Y., Lv, Z., Studies on the antiatherosclerotic effects of chitosan ester. Chin J Mar Drugs 20:1 (2001), 12–16.
60. Hu, J., Geng, M., Yu, G., Li, Y., Xu, J., Study on the antioxidant effect of chitin derivative (916) in vitro. Chin J Mar Drugs 20:1 (2001), 25–27.
61. Hu, J., Geng, M., Chen, K., Ran, Z., Xu, J., Guan, H., Prophylactic effects of chitin derivative “916” on atherogenesis in hypercholesterolemic rabbits. Chin J Mar Drugs 19:3 (2000), 18–21.
62. Ren, D., Geng, M., Du, G., Zhang, J., Polysaccharide sulfate 916 inhibits neutrophil-endothelial adhesion. Chin Med J (Engl) 115:12 (2002), 1855–1858.
63. 2. Chin Med J (Engl) 15:4 (2002), 614–616.
64. Yang, Z., Using HPCE Method to Study Marine Sulfated Polysaccharide 916 and Human Serum Albumin Interactions. 2010, Ocean University of China, Qingdao.
65. Sun, W., The Influence of Marine Sulfated Polysaccharide 916 on Exterior and Interior Pharmacokinetics of Lovastatin in Rats. 2008, Ocean University of China, Qingdao.
66. Zhang, R., The Influence of Marine Sulfated Polysaccharide 916 on the Pharmacokinetics of Pravastatin in Rats. 2008, Ocean University of China, Qingdao.
67. Yu, M., Wang, Y., Ma, F., Yu, W., Jiang, T., LV, Z., Pharmacokinetics, tissue distribution and excretion study of fluorescein-labeled PS916 in rats. Curr Pharm Biotechnol 18:5 (2017), 391–399.
68. Li, P.L., Li, C.X., Xue, Y.T., et al. An HPLC method for microanalysis and pharmacokinetics of marine sulfated polysaccharide PSS-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles in rat plasma. Mar Drugs 11:4 (2013), 1113–1125.
69. Li, C., Sun, Y., Guan, H., Progress of marine drug propylene glycol alginate sodium sulfate (PSS) and inspiration. Chin Bull Life Sci 24:9 (2012), 1019–1025.
70. Chen, J., Dynamic observation of hemorrheology in patients with cerebral infarction treated by PSS. Chin Pract Med 7:14 (2012), 159–160.
71. Lin, C., Guan, H., Li, H., Yu, G., Gu, C., Li, G., The influence of molecular mass of sulfated propylene glycol ester of low-molecular-weight alginate on anticoagulant activities. Eur Polym J 43:7 (2007), 3009–3015.
72. Xu, J., Zhou, Q., Xu, C., et al. Efficacy of polysaccharide sulfate for acute cerebral infarction and comparison of four items plasma biomoleculars in before and after treatment. Chin J New Drugs Clin Remed 21:10 (2002), 591–594.
73. Zhang, X., Wang, Y., Guo, A., Liu, Z., Zhang, B., Guo, Y., Clinical observation of 50 hyperlipidemia patients injected polysaccharide sulfate. Hebei Med 14:11 (2011), 1473–1477.
74. Zhai, H., Duan, Y., Wang, Y., Zhang, Y., The effect of patients with diabetic nephropathy treated by polysaccharide sodium. J Pract Med Technol 14:19 (2007), 2535–2536.
75. Liu, B., Zhang, Y., Zang, H., et al. Neuroprotective role of PSS following cerebral ischemic reperfusion in rats. J Clin Neurol 18:5 (2005), 363–366.
76. Zhang, C., Jiang, L., Liu, K., et al. Effect of polysaccharide sulfate on insulin-resistance in treatment of type 2 diabetes mellitus and hyperlipidemia. Chin J Clin Pharmacol 12:1 (2003), 24–26.
77. San, X., Lin, S., Gao, P., Effect of PSS on high sensitivity C reactive protein in patients with acute cerebral infarction. Mod J Integr Tradit Chin West Med 19:32 (2010), 4729–4730.
78. Zhang, J., Zhang, A., Chen, S., et al. The polysaccharide sulfate enhance neovascularization of aeidie fibroblast growth factor. Chin J Cardiovasc Med 2:1 (1997), 12–14.
79. Li, P., Li, C., Xue, Y., et al. Preparation, characterization and pharmacokinetics of fluorescence labeled propylene glycol alginate sodium sulfate. J Ocean Univ China 13:4 (2014), 683–690.
80. Xu, B., Xu, Q., Yan, Y., et al. Effect of ASA combined with PSS on the prevention of ischemic cardio-cerebrovascular diseases among high-risk population. Occup Health 23:3 (2007), 166–168.
81. Bai, Z., Zhang, H., Ge, L., Han, H., Effect of aspirin combined with PSS on prevention of recurrent cerebral infarction. Shandong Med J 49:32 (2009), 100–101.
82. Jin, M., Sui, X., Observation on therapeutic effect of sodium alginate diester combined with benzafibrate on dyslipidemia. Heilongjiang Med Pharm, 31(3), 2008, 91.
83. Liang, Y., Clinical observation of bezafibrate combined with propylene glycol alginate sodium in the treatment of acute hyperlipidemic pancreatitis. Intern Med Chin 6:5 (2011), 430–433.
84. Sun, J., Jiang, L., Effect of cinepazide maleate combined with alginic sodium diester on treatment of otogenic vertigo. Clin J Med Off 43:10 (2015), 1010–1012.
85. Zhang, P., Xia, Q., Zhao, X., Advances in the study of the pharmacological and clinical application of PGMS. Jiangsu Pharmacol Clin Res 9:1 (2001), 38–40.
86. Jiang, G., Yuan, W., Zhang, S., The study of antithrombotic effect and mechanism of propylene glycol mannate sufate. Chin J Mar Drugs 1 (1994), 6–13.
87. Weng, J., Zhu, X., Lin, Y., Wang, Z., Effects of PGMS on the functions of human platelets and endothelial cells. Acta Acad Med Sin 19:6 (1997), 414–418.
88. Zhang, M., Lin, H., Zhang, X., Wei, X., Protective effect of PGMS on acute cerebral ischemia reperfusion injury in rats. China Foreign Med Treat 22 (2011), 30–31.
89. Zhou, W., Wang, H., Du, X., Dong, W., Effects of propylene glycol mannite sulfate on the expression of tumor necrosis factor-α and interleukin-1β in the rat with diabetic retinopathy. Int J Ophthalmol 16:8 (2016), 1444–1448.
90. Sheng, S., Li, Y., Ma, J., Yuan, W., Studies on the in Vivo pharmackinetics of propylene glycol mannurate sulfate in mice. Chin J Mar Drugs 14:2 (1995), 15–17.
91. Gong, H., Liu, X., Effect of PGMSr on blood lipid level and hemorheology in hyperlipidemia. Clin Focus 15:11 (2000), 513–514.
92. Tan, L., Wang, C., Zhang, W., Effects of mannose ester on blood lipids, serum oxidized low density lipoprotein, C-reactive protein in patients with coronary heart disease complicated with hyperlipidemia. Chin J Mar Drugs 27:3 (2008), 28–30.
93. Chen, Z., Zhao, X., Yang, S., Liu, Q., Guan, H., Li, G., An exploration on the mechanism of antioxidant effect of PGMS in patients with chronic cor-pul-monale. Chin J Mar Drugs 1 (1997), 50–52.
94. Zhao, X., Yu, G., Guan, H., Yue, N., Zhang, Z., Li, H., Preparation of low-molecular-weight polyguluronate sulfate and its anticoagulant and anti-inflammatory activities. Carbohydr Polym 69:2 (2007), 272–279.
95. Zhao, X., Yu, G., Yue, N., Guan, H., Effects of low-molecular-weight polyguluronate sulfate on experimental urolithiasis in rats. Urol Res 35:6 (Dec 2007), 301–306.
96. Cao, L.C., Boevé, E.R., Schröder, F.H., Robertson, W.G., Ketelaars, G.A.M., Bruijn, W.C.D., The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. J Urol 147:6 (1992), 1643–1646.
97. Boevé, E.R., Schröder, F.H., Cao, L.C., Deng, G., Bruijn, W.C.D., Effect of two new polysaccharides on growth, agglomeration and zeta potential of calcium phosphate crystals. J Urol 155:1 (1996), 368–373.
98. Verkoelen, C.F., Romijn, J.C., Cao, L.C., Boevé, E.R., De Bruijn, W.C., Schröder, F.H., Crystal-cell interaction inhibition by polysaccharides. J Urol 155:2 (1996), 749–752.
99. Wu, L., Wang, W., Zhang, X., Zhao, X., Yu, G., Anti-HBV activity and mechanism of marine-derived polyguluronate sulfate (PGS) in vitro. Carbohydr Polym 143 (Jun 5 2016), 139–148.
100. Guan H, Li G, Zhao X. A method for preparation PGS and its application. n.d. CN. Patent. 200310105718.9.2004-11-10.
101. Miao, B., Li, J., Fu, X., Gan, L., Xin, X., Geng, M., Sulfated polymannuroguluronate (SPMG), a novel anti-acquired immune deficiency syndrome (AIDS) drug candidate, inhibits T cell apoptosis via combating oxidative damage of mitochondria. Mol Pharmacol 68:6 (2005), 1716–1727.
102. Geng, M., Li, F., Xin, X., Li, J., Yan, Z., Guan, H., The potential molecular targets of marine sulfated polymannuroguluronate interfering with HIV-1 entryInteraction between SPMG and HIV-1 rgp120 and CD4 molecule. Antiviral Res 59:2 (2003), 127–135.
103. Xin, X., Geng, M., Guan, H., Li, Z., Study on the mechanism of inhibitory action of 911 on replication of HIV-1 in vitro. Chin J Mar Drugs 19:4 (2000), 15–18.
104. Xin, X., Ding, H., Geng, M., Liang, P., Li, Y., Guan, H., Studies of the anti-AIDS effects of marine polysaccharide drug 911 and its related mechanisms of action. Chin J Mar Drugs 19:6 (2000), 4–8.
105. Liu, H., Geng, M., Xin, X., et al. Multiple and multivalent interactions of novel anti-AIDS drug candidates, sulfated polymannuronate (SPMG)-derived oligosaccharides, with gp120 and their anti-HIV activities. Glycobiology 15:5 (May 2005), 501–510.
106. Lu, C., Li, J., Sun, Y., et al. Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. Biochem Pharmacol 74:9 (2007), 1330–1339.
107. Hui, B., Li, J., Geng, M., Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, decreased vulnerability of PC12 cells to human immunodeficiency virus Tat protein through attenuating calcium overload. J Neurosci Res 86:5 (Apr 2008), 1169–1177.
108. Wu, Y., Ai, J., Zhao, J., et al. Sulfated polymannuroguluronate inhibits tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad. Acta Pharmacol Sin 32:5 (May 2011), 647–654.
109. Zhong, J., Xie, M., Gan, C., Research status and prospect of seaweed sulfated polysaccharide in anti HIV activity. Chin J Pharm 37:12 (2002), 884–887.
110. Jiang, F., Xu, X., Li, L., Yuan, W., Study on “911” anti-HBV effect in HepG2.2.15 cells culture. Mod Prev Med 30:4 (2003), 517–518.
111. Liu, B., Wang, C., Zhang, H., et al. Preparation and identification of a series of mannose glucuronic acid oligosaccharides. Chem J Chin Univ 27:3 (2006), 485–487.
112. Kong, L., Geng, M., Mou, L., Xin, X., Yang, N., Zuo, P., Effects of acidic oligose on differentially expressed genes in the mice model of Alzhemier’ s disease by microarray. Acta Pharm Sin 40:12 (2005), 1105–1109.
113. Geng, M., GV-971, a new drug against Alzheimer's disease. Chin J Pharmacol Toxicol 31:5 (2017), 459–460.
114. Liu, P., Establishment of Immunoassay for Clinical Pharmacokinetic Studies of Oligomannurarate(971), a Novel Anti-Alzheimer's Drug Candidate. 2009, Ocean University of China, Qingdao.
115. Hao, C., Hao, J., Wang, W., et al. Insulin sensitizing effects of oligomannuronate-chromium (III) complexes in C2C12 skeletal muscle cells. PLoS One, 6(9), 2011, e24598.
116. Zhao X, Yu G, Guan H, Li G, Hao C. A marine oligosaccharide compounds with activity against type 2 diabetes. n.d. CN. Patent 200910177710.0.2010-2-17.
117. Cui, H., Studies on the Preparation and Anti-Type 2 Diabetes Mechanisms of Marine Oligosaccharide Derivatives. 2011, Ocean University of China, Qingdao.
118. Sun, S., Zhao, X., Li, G., et al. Microanalysis of oligosaccharide HS203 in beagle dog plasma by postcolumn fluorescence derivatization method. Carbohydr Polym 89:2 (2012), 661–666.
119. Saito, A., Munakata, H., Analysis of plasma proteins that bind to glycosaminoglycans. Biochim Biophys Acta 1770:2 (Feb 2007), 241–246.
120. Mulloy, B., Hogwood, J., Gray, E., Lever, R., Page, C.P., Pharmacology of heparin and related drugs. Pharmacol Rev 68:1 (Jan 2016), 76–141.
121. Ori, A., Wilkinson, M.C., Fernig, D.G., A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem 286:22 (2011), 19892–19904.
122. Peysselon, F., Ricard-Blum, S., Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol 35 (Apr 2014), 73–81.
123. Esko, J.D., HP, J., Linhardt, R.J., Proteins that bind sulfated glycosaminoglycans. Varki, A., Cummings, R.D., et al. (eds.) Essentials of Glycobiology, 2015, Cold Spring Harbor, NY, 493–502.
124. Zhang, L., Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. Prog Mol Biol Transl Sci 93 (2010), 1–17.
125. Fareed, J., Hoppensteadt, D.A., Fareed, D., et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 34:1 (Feb 2008), 58–73.
126. Spillmann, D., Heparan sulfate: anchor for viral intruders?. Biochimie 83:8 (2001), 811–817.
127. Zhang, Y., Zhang, M., Tan, L., Pan, L., Zhang, L., The clinical use of fondaparinux: a synthetic heparin pentasaccharide. Prog Mol Biol Transl Sci 163 (2019), 41–53.
128. Zhang, M., Zhang, Y., Zhang, L., Tian, Q., Mushroom polysaccharide lentinan for treating different types of cancers: a review of 12 years clinical studies in China. Prog Mol Biol Transl Sci 163 (2019), 297–328.
129. Zhang, Y., Jiang, Y., Zhang, M., Zhang, L., Ganoderma sinense polysaccharide: an adjunctive drug used for cancer treatment. Prog Mol Biol Transl Sci 163 (2019), 165–177.
130. Zeng, P., Chen, Y., Zhang, L., Xing, M., Ganoderma lucidum polysaccharide used for treating physical frailty in China. Prog Mol Biol Transl Sci 163 (2019), 179–219.
131. Yang, D., Zhou, Z., Zhang, L., An overview of fungal glycan-based therapeutics. Prog Mol Biol Transl Sci 163 (2019), 135–163.
132. Yang, D., Liu, Y., Zhang, L., Tremella polysaccharide: the molecular mechanisms of its drug action. Prog Mol Biol Transl Sci 163 (2019), 383–421.
133. Li, X., Ma, L., Zhang, L., Molecular basis for Poria cocos mushroom polysaccharide used as an antitumor drug in China. Prog Mol Biol Transl Sci 163 (2019), 263–296.
134. Guo, Z., Zang, Y., Zhang, L., The efficacy of Polyporus Umbellatus polysaccharide in treating hepatitis B in China. Prog Mol Biol Transl Sci 163 (2019), 329–360.
135. Bishop, J.R., Schuksz, M., Esko, J.D., Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446:7139 (2007), 1030–1037.
136. Lv, Z., Studies on Fluorescent Labeling and Pharmacokinetics of Marine Sulfated Polysaccharide PS916. 2008, Ocean University of China, Qingdao.